Pancreatic Enzyme Suppletion in Pancreatic Cancer — EPC  

Adenocarcinoma of the Pancreas Clinical Trial

Official title: Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy

Status Withdrawn

Clinical Trial Summary

This study will evaluate the effect of immediate pancreatic enzyme suppletion on the physical and mental health status and survival of patients who are diagnosed with pancreatic cancer and are highly likely to develop exocrine pancreatic insufficiency during their disease process.

Clinical Trial Description

Weight loss in cancer is caused by primary tumour effects and secondary effects (e.g. side effects of treatment, mechanical and intestinal obstruction). In pancreatic cancer, additional weight loss and malnutrition may be due to the development of exocrine pancreatic insufficiency (EPI). The presence of EPI in pancreatic cancer is frequently overlooked, because the focus of treatment is directed at possible surgery or chemotherapy and its potential side effects. Although studies have proven that pancreatic enzymes may prevent or decrease weight loss, they are seldom being prescribed. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of the Pancreas
• Exocrine Pancreatic Insufficiency
• Normal Pancreatic Exocrine Function
• Pancreatic Neoplasms

• NCT number: NCT01401387
• Study type: Interventional
• Source: Foundation for Liver Research
• Status: Withdrawn
• Phase: Phase 4
• Start date: October 2011
• Completion date: May 2013